Therapeutic dose range of nefazodone in the treatment of major depression

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 2, 1996, Pages 6-9

  Robinson, Donald S ^a   Marcus, Ronald N ^b,c   Archibald, Donald G ^b   Hardy, Sterling A ^b  

^a Bristol Myers Squibb P ^*

^b BRISTOL MYERS SQUIBB   (United States)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; NEFAZODONE; PLACEBO; SEROTONIN ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEDATION; TREATMENT OUTCOME; VISUAL IMPAIRMENT; XEROSTOMIA;

AGE FACTORS; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; TREATMENT OUTCOME; TRIAZOLES;

EID: 0030002854     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Taylor DP, Carter RB, Eison AS, et al. Pharmacology and neurochemistry of nefazodone, a novel ancidepressant drug, J Clin Psychiatry 1995;56 (suppl 6):3-11
2. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 1995;56(suppl 6):30-36
3. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
4. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164:802-805
5. Cohn CK, Robinson DS, Roberts DL, et al. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression J Clin Psychiatry 1996;57(suppl 2):15-18
6. D'Amico F, Roberts D, Robinson DS, et al. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone Psychopharmacol Bull 1990;26:147-150
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
8. Guy W. ECDEU Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
9. Leber P. Is there an alternative to the randomized trial? Psychopharmacol Bull 1991;27:3-6
10. Laska EM, Klein DF, Levine J, et al. Design issues for the clinical evaluation of psychotropic drugs. In: Prien RF, Robinson DS. eds. Clinical Evaluation of Psychotropic Agents: Principles and Guidelines. New York, NY: Raven Press; 1994
11. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996;57(suppl 2):31-38